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Abstract: We evaluated the effect of low-frequency rTMS on motor signs in Parkinson’s disease (PD), under a 
double-blind placebo-controlled trial design. PD patients were randomly assigned to received either real (n 5 9) or 
sham (n 5 9) rTMS for 10 days. Each session comprises two trains of 50 stimuli each delivered at 1 Hz and at 90% of 
daily rest motor threshold using a large circular coil over the vertex. The effect of the stimulation, delivered during 
the ON-period, was evaluated during both ON and OFF periods. Tests were carried out before and after the 
stimulation period, and again 1 week after. The effect of the stimulation was evaluated through several gait variables 
(cadence, step amplitude, velocity, the CVstride-time, and the turn time), hand dexterity, and also the total and motor 
sections of the UPDRS. Only the total and motor section of the UPDRS and the turn time during gait were affected 
by the stimulation, the effect appearing during either ON or OFF evaluation, and most importantly, equally displayed 
in both real and sham group. The rest of the variables were not influenced. We conclude the protocol of stimulation 
used, different from most protocols that apply larger amount of stimuli, but very similar to some previously reported 
to have excellent results, has no therapeutic value and should be abandoned. This contrasts with the positive reported 
effects using higher frequency and focal coils. Our work also reinforces the need for sham stimulation when 
evaluating the therapeutic effect of rTMS.  
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The therapeutic role of repetitive transcranial magnetic stimulation (rTMS) in motor symptoms in 
Parkinson’s disease (PD) is currently not well defined. Although there have been a significant number of 
studies performed, the heterogeneity in their protocols and conflicting results do not reveal clear 
conclusions about the effectiveness of the technique. However, studies involving single session rTMS1,2 
suggest that repeated rTMS might offer significant improvements in parkinsonian patients. These studies 
have utilized a number of different paradigms, changing variables such as stimulus intensity, duration, 
frequency, location and even coil type, not forgetting the actual tests carried out, the drug status of the 
patients and the degree of disease severity. With multiple sessions the number of variables increases still 
further, greatly enlarging the parameter space. It is therefore unsurprising that studies utilizing repeated 
sessions of rTMS have shown mixed results, but including some apparent successes.3–8 An important 
aspect of many studies (largely overlooked) is the absence of a properly controlled placebo group. We 
therefore adopted an experimental paradigm, which attempts to build upon previously successful multiple 
session rTMS protocols,3,4,7 with the addition of an equally large randomly assigned control group, given 
‘‘sham’’ rTMS. Our study tested the effect of 10 sessions of low-frequency rTMS, stimulating patients 
with a large round coil over the vertex at a frequency of 1 Hz (utilized apparently successfully by Mally 
and Stone3,4 and Mally and colleagues7), but normalizing intensity as a function of RMT, in a double-
blind fashion. In short, we chose our protocol to try to replicate earlier work by Mally and colleagues,3,4,7 
while trying to change those methodological elements, which we felt accounted for their ‘‘positive’’ 
results. Also, given the suggestion of a ceiling effect of medication, 9 we evaluated motor symptoms 
during both ON and OFF phases, as done before with other stimulation protocols and target areas8,10–12 (of 
important therapeutic relevance). Finally, since rTMS has been reported to be more effective when 
applied during the ON phase,8 we stimulated only during ON. 
PATIENTS AND METHODS 
Patients 
From a pool of 25 volunteer patients with PD, 19 met the criteria (see later) and 18 (nine real, nine 
sham) completed the study (Fig. 1). Patients had to match the primary diagnosis of PD (based on medical 
records following established diagnostic criteria); being at stages II–IV according to the criteria of Hoehn 
and Yahr during OFF; and be able to cope with OFF periods. Patients were not taking antidepressant 
medication. Exclusion criteria were as follows: previous experience with TMS, implanted devices, pump-
based drug administration systems, history of seizures, dementia (MMSE < 24), arthromuscular deficit or 
joint prostheses, presence of dyskinesias disturbing stimulation or motor evaluation, unpredictable motor 
fluctuations, and medication change within the month prior to the start of the experiment. 
Patients were required to complete all sessions and could not change their medication regime during 
the study. They enrolled into the program in groups of up to four patients every 3 weeks and were 
randomly assigned to receive real or sham stimulation. The distribution of the two last groups were 
counterbalanced (based on UPDRS score), avoiding a possible imbalance due to chance. 
 
 
 
 
Procedure 
Motor evaluations were carried out three times: before the 10 stimulation sessions (PRE), after 
stimulation sessions (POST), and 1 week after POST (POST-2). 
Evaluations were performed at weekends, 1 day in OFF, the other in ON; allocated to ON–OFF or 
OFF–ON after randomization. This order was reproduced at POST and POST-2. 
ON evaluation was performed when the effect of medication was optimal, based on patients self-
report13 and neurological examination. 
OFF evaluation was performed after one night with holding medication (≥12 hours) (10 patients took 
controlled release drugs at the last intake of the day, which was not taken the day before OFF evaluation; 
five patients wore transdermal patches which were removed the day before OFF evaluation, ≥12 hours); 
OFF was confirmed by patients and neurological evaluation. 
TMS (Monday to Friday for 2 weeks) was applied in the morning during self-rated ON periods, 
between 1 and 2 hours after medication intake.8 The protocol was in accord with the Helsinki declaration 
and approved by the University of A Coruña ethics committee. Patients signed consent forms. 
Evaluations 
Motor tests—walking, hand dexterity, and motor section of the UPDRS. 
 
• Walking: Walk 5 m, turn around (left), walk back 5 m, turn around (right), and walk 5 m. Each trial 
therefore comprised 15 m and two turns. Subject performed this three times, resting 2 minutes 
between trials. The task was performed using the preferred walking pattern. The instruction given 
was: ‘‘Walk along the corridor as you normally do, turn around the cone at the end, come back 
walking as you normally do, turn around this other cone, and go back again walking as you normally 
do to touch the button on the wall’’ (Fig. 2). Before the three recording trials, one practice trial was 
performed. 
• Hand dexterity utilized the Purdue Pegboard. Subjects had to place as many pegs as possible, 
sequentially into a row of holes within 30 seconds. The number of pegs was recorded. Subjects 
performed this three times for each hand. 
• UPDRS: The total score and the motor section of the scale were taken into account. 
• Evaluation was undertaken by authors PA and JV, blind to the stimulation protocol. 
 
 
FIG. 2. Representation of the gait procedure. 
Stimulation 
Stimulation was applied from behind, with a round coil (see apparatus) centered over the vertex (by 
authors K.L.G. and J.C.). Each session, 100 pulses were delivered in trains of 50 at 1 Hz. One was 
delivered clockwise and the other anticlockwise with a 5-minute pause inbetween. Intensity was set at 
90% of rest motor threshold (RMT) defined as the lowest intensity eliciting a clear response of 50 µV 
peak-topeak amplitude in the first dorsal interosseus of the less affected side, in 5/10 of successive trials. 
This was measured daily before stimulation.  
For sham stimulation, two coils were used. One coil, unconnected to the stimulator, was placed over 
the vertex (as earlier). The second coil (connected to the stimulator, but set at 35% output) was placed in 
direct contact to the first, but tilted 90º. Thus, the patient could feel only one coil flat over the head (as 
had been explained to all patients prior to the study). During the sham protocol, EMG settings were 
maintained and some single pulses were delivered (mimicking RMT determination). We have now been 
made aware of the availability of specific placebo sham coils.14 
Apparatus 
For gait evaluation, the recording system comprised footswitches worn as insoles in the shoes 
connected to a radio-transmitter attached to the subjects’ belt. Data (sampled at 1 KHz) were sent to a 
computer receiver allowing stride cycle time to be registered.15 Two photocells, placed 5-m apart, were 
connected to the recording system (Fig. 2). 
Hand dexterity was measured as described earlier. TMS stimulation used a High Power 90 mm round 
coil powered by a Magstim Rapid (The Magstim Company, Whiyland, UK). Motor-evoked potentials 
(MEP) were registered using Ag/Cl surface electrodes attached with a belly tendon montage. 
Analyzed Variables 
For gait: 
 
• Velocity, time to cover the straight parts of the task, data obtained from the photocells. 
• Cadence, calculated from data obtained through footswitches, corresponding to the straight part of the 
task. 
• Step amplitude, derived from velocity and cadence. 
• Turn time, obtained from the successive activation of the photocells (before and after turns). 
• The CVstride-time, obtained from the footswitches data of the straight section, defined as follows: 
 
CV(%) = (SD/mean) x 100 
All gait values were the mean of three trials. Values for manual dexterity were the averages for the 
three trials of the Peg Board test, averaged across both hands. Total and motor scores from the UPDRS 
were analyzed. 
Data Analysis 
To check homogeneity between groups in PRE a Students ‘‘t’’ for independent samples was applied 
for each variable; either in ON or OFF. 
To evaluate stimulation effectiveness, a three-way ANOVA with repeated measures was performed 
for each variable; two within-subjects factors were defined, evaluation with three levels (PRE, POST, and 
POST-2), and drug with two levels (ON and OFF). The between subjects factor was group (real or sham 
stimulation). For total score of UPDRS (assessed during ON), suppressing factor drug reduced to a two-
way ANOVA with repeated measures. 
Normality of distribution was check by K–S test. Greenhouse-Geisser correction was applied when 
sphericity was violated. SPSS was used for statistical analysis. Significance was set at P < 0.05. 
RESULTS 
Groups Homogeneity: PRE Real Versus Sham 
In the PRE tests, both groups, real and sham, were not significantly different for all analyzed variables 
(in ON and OFF periods, see Fig. 3 and Table 1). Thus, at the beginning of the program, real and sham 
groups had comparable grades of ‘‘disability.’’  
 
 
FIG. 3. Values (means, SD) for each variable before stimulation (PRE). Black bars, real stimulation; open bars, sham stimulation. 
There were no significant differences between groups at PRE for any variable, either during ON or OFF periods (total score of 
UPDRS was assessed only during ON). Groups were therefore comparable before stimulation (see also Table 1). 
Effect of the Stimulation Protocol 
Variables Not Affected by the Protocol 
A number of variables were unaffected by rTMS, in either ON or OFF tests, and this was seen in both 
real and the sham groups: step amplitude, cadence, velocity, and the CVstride-t ime. The same was seen for 
hand dexterity (Fig. 4 and Table 2). Evaluation * drug interaction was not significant in any variable, 
proving the lack of effect was not dependent on the status of the medication, but also proving TMS did 
not alter drug influence on the PD (Table 2). No significant interaction involving group was detected, so 
the aforementioned description occurred for both groups, real and sham (Table 2). 
There were some significant effects of factor drug, showing the effectiveness of medication: step 
amplitude F(1,16) = 4.749, P = 0.045, and for the Pegboard F(1,16) = 6.837, P = 0.019. In other tests, the 
effect of drug did not reach significance; in both cases, these effects were observed in both groups. 
These results show that the rTMS protocol did not affect these variables.  
TABLE 1. Groups homogeneity 
 t P-value 
Gait velocity   
ON t(16) = 0.027 P = 0.979 
OFF t(16) = 0.378 P = 0.710 
Step cadence   
ON t(16) = 0.249 P = 0.807 
OFF t(11.241) = 0.277 P = 0.787 
Step amplitude   
ON t(16) = 0.098 P = 0.923 
OFF t(16) = 0.356 P = 0.726 
CV stride time   
ON t(16) = 0.011 P = 0.991 
OFF t(13.752) = 0.920 P = 0.374 
Turn time   
ON t(16) = 0.838 P = 0.414 
OFF t(16) = 0.991 P = 0.336 
Pegboard   
ON t(16) = 0.973 P = 0.345 
OFF t(16) = 1.229 P = 0.237 
UPDRS   
ON t(16) = 0.036 P = 0.971 
UPDRS-III   
ON t(16) = 0.147 P = 0.885 
OFF t(16) = 1.198 P = 0.248 
   
 
PRE real versus sham. Between groups (real vs. sham) before stimulation (PRE). t and 
associated P-values are shown in ON and OFF periods, except UPDRS, evaluated only 
during ON. Lack of significance shows groups were comparable at PRE, before the 
stimulation period. 
Variables Affected by the Protocol 
Conversely, some other variables were indeed affected by the protocol, as a main effect of factor 
evaluation was seen (Table 2). When this happened, the evaluation * drug interaction was always not 
significant (Table 2), proving the effect of the protocol was present to the same extent either in ON or 
OFF phases, thus answering one of our stated objectives. 
However, the key element involved possible interactions with factor group. No significant interaction 
involving Group was seen (Table 2), proving behavior of sham and real groups were the same, suggesting 
a strong placebo effect as cause of improvement in the signs (Fig. 4, UPDRS_III and the TT during gait, 
see Table 2 for a summary). A significant effect of factor drug was also in the UPDRS_III (F(1,16) = 
25.846, P < 0.001) proving a better performance in presence of medication; this was not achieved for TT. 
Finally, for all variables analyzed, affected by the protocol or not, the factor group was not significant 
for any variable [logical, since groups were homogenous at the beginning (PRE) and all effects 
(significant or not) affected both groups similarly (see earlier and Table 2)]. 
DISCUSSION 
The primary objective of this study was a re-examination of the results obtained by previous studies 
showing significant beneficial effects on patients with PD using low-frequency rTMS,3,4 but with the 
addition of a properly balanced placebo group of ‘‘untested’’ patients, evaluated using a blind paradigm. 
A secondary objective was to examine the possibility9 that the medication and its timetabling with respect 
to TMS could cause a ‘‘ceiling’’ effect, such that the true ‘‘effect’’ of rTMS would not be seen. 
Therefore, we decided to evaluate the effect of the treatment both in ON and OFF periods.8,10–12 
Dealing with the second objective first, the results we obtained showed that effects did not depend on 
medication status. Our results match reasonably well those of Tergau et al.9 who could not prove effects 
of stimulation on motor function with the same type of coil, using high and low frequencies. Our data 
supports also earlier findings by Lomarev et al.8 (who actually used a different coil and stimulation  
frequency). It is also worth repeating that our stimulation was performed when patients were in the ON 
phase, following the report by Lomarev et al.8 that this was more effective rather than in the OFF phase. 
 
FIG. 4. The effect of the rTMS on the different variables before starting the period of stimulation (PRE), after the 10 sessions of 
stimulation (POST), and 1 week after finishing the period of stimulation (POST-2). Solid ON, dashed OFF (total score of UPDRS 
assessed during ON). Mean and SD are plotted for both groups pooled as no significant interactions involving factor group (real–
sham) were found (see also Table 2). 
 
TABLE 2. Effect of the stimulation protocol 
 Evaluation Drug Group Evaluation * drug Evaluation * drug * group (for UPDRS evaluation * group) 
      
Gait velocity F(1.193,19.082) = 3.472, P = 0.072 F(1,16) = 2.694, P = 0.120 F(1,16) = 0.000, P = 0.996 F(2,32) = 2.129, P = 0.136 F(2,32) = 0.943, P = 0.400 
Step cadence F(2,32) = 2.172, P= 0.131 F(1,16) = 0.431, P = 0.521 F(1,16) = 0.000, P = 0.987 F(2,32) = 1.719, P = 0.195 F(2,32) = 0.078, P = 0.925 
Step amplitude F(1.175, 18.794) = 1.758, P = 0.202 F(1,16) = 4.749, P = 0.045 F(1,16) = 0.001, P = 0.973 
F(1.492,23.866) = 1.123, 
P = 0.326 
F(1.492,23.866) = 1.123, 
P = 0.326 
CV stride time F(2,32) = 0.228, P = 0.797 F(1,16) = 0.467, P = 0.504 F(1,16) = 0.009, P = 0.925 F(1.499,23.992), = 0.117 P = 0.833 
F(1.499,23.992) = 0.117, 
P = 0.833 
Turn time F(2,32) = 3.334, P = 0.048 F(1,16) = 1.335, P = 0.265 F(1,16) = 0.232, P = 0.637 F(2,32) = 1.436, P = 0.252 F(2,32) = 0.283, P = 0.756 
Pegboard F(2,32) = 1.982, P = 0.152 F(1,16) = 6.837, P = 0.019. F(1,16) = 1.652, P = 0.217 F(2,32) = 0.541, P = 0.587. F(2,32) = 1.080, P = 0.352 
UPDRS F(2,32) 5 13.077, P < 0.001 NA, it was assessed during ON periods F(1,16) = 0.737, P = 0.403 
NA, it was assessed 
during ON periods 
aF(2,32) = 0.704, P = 0.502 
UPDRS-III F(2,32) = 24.470, P < 0.001 F(1,16) = 25.846, P < 0.001) F(1,16) = 0.355, P = 0.560 F(2,32) = 0.226, P = 0.799 F(2,32) = 1.482, P = 0.242 
      
 
The values in bold indicate significant effects.  
*Interaction evaluation * group for UPDRS, assessed only during ON periods. Turn time, UPDRS total and motor section were significantly affected by stimulation independently of ON or OFF. Importantly, evaluation 
* drug * group was not significant, showing that the effect was equal in real and sham. 
Notably, our main objective was to reinvestigate the effectiveness or otherwise of a low-frequency 
rTMS stimulation protocol, which appeared to offer significant therapeutic success, coupled with minimal 
patient inconvenience, as previously published by Mally et al.3,4 If an effect of rTMS shows therapeutic 
power, it seems likely that it will also be dependent on dose quantity,16,17 so that given reported safety 
guidelines,18 a protocol with low-stimulation frequency would be advantageous. In our case, however, we 
added a controlled for possible placebo effects. Our data clearly shows that the low frequency, short 
stimulus train was no more effective than the placebo, therefore this protocol has no therapeutic effect on 
motor signs in PD, calling into question the results of the previous studies. 
Many of the variables analyzed involving gait (cadence, step amplitude, velocity, and variability of 
stride cycle time), and hand dexterity were unaffected by stimulation; while for those affected, 
improvements seem due to a placebo response. This was clearly seen in turn time, UPDRS motor section 
and total score. This contrasts with other results using treatment with circular coils applied over the 
vertex,3,4,7 but agrees with others.9,19 
Reasons explaining these discrepancies may be several. In some studies, Mally et al. used a different 
stimulation intensity to ours—indeed, they did not individualize intensity to motor thresholds.4,7 
Moreover, elsewhere they used 20% of RMT,3 significantly lower than our 90%. Other possibilities lie in 
technical details of coil and TMS delivery. Kammer et al.20 showed effects related to monophasic versus 
biphasic pulses; different pulse waveforms affect neurophysiological variables, 21,22 for instance 
differentially affecting determination of motor threshold.23 We delivered biphasic pulses, whereas Mally 
and Stone3 used a model allowing waveform selection, but did not report the waveform used. While the 
differences could be explained if they had used monophasic pulses, their waveform would then be the 
same as used by Okabe et al.,19 who like us, saw no beneficial results from low-frequency stimulation. 
Another variable is current direction.24 We applied both clockwise and anticlockwise to have the same 
effect over both hemispheres, much like Tergau et al.9 and Okabe et al.19 Mally and coworkers3,4,7 did not 
report direction. The number of pulses per day in our protocol was 100, the protocol being similar to 
others cited earlier. 3,4,7,19 Tergau et al.9 utilized more pulses (1000), but with negative results; and it is 
therefore important to point out while interhemispheric excitability changes were shown to be associated 
with rTMS frequency, this might be independent of pulse number.25 Lang et al.26 showed differential 
changes in some neurophysiological variables using two different figure of eight coils (Magstim or 
Dantec) suggesting a possible explanation for different results, as we used Magstim and Mally Dantec. 
However, our results with Magstim are similar to those using Dantec.9 Thus, we must emphasize that the 
most noticeable difference between the ‘‘successful’’ underdosed studies and ours remains our use of the 
double blind, placebo-controlled experimental paradigm, which Mally and coworker did not use. 
Basically, our results contrast with some other controlled studies which reported improvement in 
parkinsonian signs, using figure-of-eight coils and high stimulation frequencies.5,6,8 Clearly, the type of 
coil can have a role27,28; Lomarev et al.8 and Khedr et al.5,6 used figure-of-eight (focal) coils to stimulate 
the motor cortex with significant results. While accepting that the studies by Khedr et al.5,6 and Lomarev 
et al.8 were well controlled, we understand the stimulation protocols used by them are difficult to control 
with sham protocols, given that they used an intensity of 100% RMT. 
We agree that future experiments should be performed to explore the therapeutic role of rTMS in PD 
(e.g., see Fregni et al.29), but argue that such studies should focus on higher frequencies and/or longer 
durations of stimulation; also patterned stimulation30 and combination of rTMS and tDCS deserves to be 
considered. 31,32 In all cases, however, the necessity of appropriate controls, as for example concluded by 
Okabe et al.19 has been reinforced by our study, for this purpose new placebo coils (with somatosensory 
stimulation 14) seem to be optimal in case of crossover designs, or when subjects are not naive to rTMS, 
which is not the case in this study. 
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